A vital spotlight is now on pharmaceutical companies to ensure patents are accurately listed in the U.S. Food and Drug Administration’s Orange Book – also known as Approved Drug Products with Therapeutic Equivalence Evaluations – following a policy statement issued by the Federal Trade Commission on September 14. The legal implications for such companies are pronounced, with potential lawsuits looming where improper listing occurs. Notably, complications surrounding patent listings are not confined to this context but are also prevalent in Hatch-Waxman litigations.
For the pharmaceutical industry, the Orange Book has a particularly special place as the authoritative guide for therapeutically equivalent, FDA-approved drugs. The potential misstep of incorrect patent listing does not just attract legal pitfalls, but also stands as a source of critical business disruption.
Legal professionals in the pharma sector would be well-advised to ensure their respective organizations are in line with this FTC policy statement. It calls for a renewed emphasis on proper protocol adherence and meticulous roster maintenance for patents within the Orange Book. Furthermore, these principles should be duly echoed within the broader scope of Hatch-Waxman litigations.
Additional details regarding the policy statement, and its specific implications for pharmaceutical businesses, can be found here.